Company Overview
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +35.04% |
| 6 Months: | +6.51% |
| 3 Months: | -6.65% |
| 1 Month: | -13.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.15 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 34.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PTHS Pelthos Therapeutics Inc. PHARMA | 24.55 | -0.86 | $93.99M | 0.00% | -31.06% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 7.41M | 9.39M | 10.91M |
| Cost of Revenue | - | - | - | - | - | - | - | 0 | - | 4.97M | 4.39M | 5.31M |
| Gross Profit | - | - | - | - | - | - | - | 0 | - | 2.43M | 5.00M | 5.59M |
| Operating Expenses | - | - | - | - | - | - | - | 1.83M | 3.23M | 17.79M | 17.00M | 18.68M |
| Operating Income | -914.58K | -777.16K | -1.29M | -1.93M | -1.76M | -2.05M | - | -1.83M | -3.23M | -15.36M | -12.00M | -13.09M |
| EBITDA | - | - | - | - | - | - | - | -1.83M | -3.23M | -14.68M | -26.05M | -6.38M |
| Interest Expense | - | - | - | - | - | - | - | 134.00K | 218.52K | 1.35M | 1.31M | 2.35M |
| Pretax Income | - | - | - | - | - | - | - | -1.97M | -3.45M | -16.70M | -28.59M | -10.24M |
| Tax Provision | - | - | - | - | - | - | - | 0 | 0 | -465.00K | -6.92M | 0 |
| Net Income | -966.56K | -953.35K | -1.42M | -2.56M | -1.77M | -1.70M | - | -1.97M | -3.45M | -16.24M | -21.66M | -10.24M |
| Diluted EPS | - | - | - | -0.55 | -3.07 | -2.93 | - | -3.21 | -5.38 | -5.30 | -6.87 | -3.09 |
| R&D Expense | 186.12K | 49.95K | 49.13K | 466.61K | 12.96K | 415.00K | - | 194.00K | 514.81K | 145.00K | - | 186.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 16.80M |
| Cost of Revenue | - | - | - | 0 | 9.37M |
| Gross Profit | - | - | - | 0 | 7.43M |
| Operating Expenses | - | 2.32M | 6.86M | 7.57M | 39.86M |
| Operating Income | - | -2.32M | -6.86M | -7.57M | -32.43M |
| EBITDA | - | -2.32M | -6.86M | -7.17M | -45.41M |
| Interest Expense | - | 140.43K | 518.51K | 786.00K | 3.01M |
| Pretax Income | - | -2.46M | -7.38M | -7.96M | -50.71M |
| Tax Provision | - | 0 | 0 | 0 | -7.39M |
| Net Income | - | -2.46M | -7.38M | -7.96M | -43.32M |
| Diluted EPS | - | -2.65 | -12.80 | -14.27 | -23.04 |
| R&D Expense | - | 391.73K | 2.58M | 1.18M | 1.23M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 55.07K | 96.39K | 1.37M | 130.40M |
| Current Assets | - | 55.07K | 96.39K | 1.37M | 53.41M |
| Cash & Equivalents | - | 55.07K | 96.39K | 513.00K | 17.97M |
| Inventory | - | - | - | 0 | 23.57M |
| Receivables | - | - | - | 0 | 8.86M |
| Total Liabilities | - | 3.76M | 6.54M | 4.08M | 91.52M |
| Current Liabilities | - | 3.76M | 6.54M | 4.08M | 25.99M |
| Long Term Debt | - | - | - | - | 31.44M |
| Total Debt | - | 540.43K | 1.27M | 2.19M | 34.83M |
| Total Equity | - | -3.71M | -6.44M | -2.71M | 38.88M |
| Shares Outstanding | - | 576.75K | 576.75K | 610.38K | 3.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.57M | -981.03K | -5.79M | -22.59M |
| Investing Cash Flow | - | - | - | 0 | -5.24M |
| Financing Cash Flow | - | 1.62M | 1.02M | 6.21M | 45.34M |
| Capital Expenditure | - | - | - | - | -8.00M |
| Free Cash Flow | - | -1.57M | -981.03K | -5.79M | -30.59M |
| Net Change in Cash | - | 55.07K | 41.32K | 417.00K | 17.51M |
| Share Buybacks | - | - | - | 75.00K | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 44.2% |
| Operating Margin % | - | - | - | - | -193.1% |
| Net Margin % | - | - | - | - | -257.9% |
| ROE % | - | 66.3% | 114.5% | 293.1% | -111.4% |
| ROCE % | - | 62.5% | 106.5% | 279.0% | -31.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 8.60% | 329.10K | $7.45M |
| 2 | Murchinson Ltd. | 7.95% | 304.30K | $6.89M |
| 3 | Ikarian Capital, LLC | 6.70% | 256.60K | $5.81M |
| 4 | Boothbay Fund Management, LLC | 2.66% | 101.98K | $2.31M |
| 5 | Vanguard Capital Management LLC | 2.54% | 97.13K | $2.20M |
| 6 | Cantor Fitzgerald, L.P. | 1.00% | 38.12K | $863.49K |
| 7 | J. Goldman & Co., L.P. | 0.99% | 38.08K | $862.40K |
| 8 | Diadema Partners LP | 0.65% | 24.77K | $561.11K |
| 9 | Knott David M., Jr. | 0.58% | 22.07K | $499.95K |
| 10 | Wexford Capital LP | 0.58% | 22.36K | $506.54K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PTHS
$PTHS stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPMmxBcGhjazF6UE9BWHdpd1lRV0dadks4aVU0MUEzbnhWbTNPSThvYmw4ZG9nZ3RCX0VjMy1iS19GZTJFUm9YQlNDRHNaVlpOWXpuWmNzQXZrUlJUTDIwX3lCTVpSbnVvN2lTc1d3NUZDSVBJZnpkd1NBZDdIV3lnaE1UcE4zUGE5UjVqdz…
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNRWxtanhvcm1yeTJISUxfZHJXMmJLM0hVY0Y2cS1MSW1hZEJ0bGlWbTBRcnF6UmROdmxOaHpfR24tZUh0bXBsMzBmS0liMEpwenE1emVlTnFDTUxfcjBqUUpIdGZMLXc0Q285NWwyUFU5TnAwTTVPLV9kNUZHYW9OQmRGRGl5b0dILXhSTF…
Pelthos sets 8:30 a.m. call to discuss Q2 results Aug. 13 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNaGlaNTFqRzlNTVQ4c2ktQVdHNXQ5bTFYemJIeHNsbDZjVkVvRExxZ2l5dnhnMWY2LU5jQXlKSG5FMlR2YmotNTVOd2NpekxRUksyTEdybDNFRlNJWlo0YVNvcV90OFRfYk1wSUtwVUJfU0VOb3JpUy05aFkxLW5sbWlSMTRGNUw2NXZ5WF…
PTHS Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1rYVhXRDhrTzBZZHlTRDcxVFN4eVFSbmM2dWZPbExBYklwTFJXcW1mTEtYdDNieUc3M0t1bElVWHdFcVZSLVNzbXh1Q25ldWZXQzNlVzVzbDhEOUxEcmxvaUwxUDJjZWxuNTdNeFBfMmYxdG9tZ2pv?oc=5" target="_blank">PTHS Fo…
Pelthos Therapeutics Inc (NYSEARCA:PTHS) Revenue Beats Estimates in Q1 2026, Net Loss Narrows - ChartMill
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPWHJnajFhdGxiYzB4YU94dDh3dGY2eFhKTWVhYUlvQVllRjJadEZYcGlQYlJ2ZUZLYUFHX0ZIZEJhcVY4OGhSemUyX19hc1dEUmpJSElLVXA5b09UUTJlSjRDaVIyYnNXamhFdTdmbEhaNWJwdjZYZFZ3UGRYak5LM0F1Y1k0LWtuUmZsan…
Pelthos Therapeutics (PTHS) Stock Forecast and Price Target 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5NZ1pMQTdNT3k2UzR5MFdBR2tXeVJkMExuQlIzR2dxUEtETTlORkVHMFdGb2hmNVVOeUZFMTd5Rk1KRW5fcXhRTTcyM0lqRnBPUGhhSnVMeVRaM2pTejNpQlBOWldCNjhWc1dKREZB?oc=5" target="_blank">Pelthos Therapeutic…
PTHS — Frequently Asked Questions
What is the current share price of Pelthos Therapeutics Inc. (PTHS)?
As of 2026-09-19 21:16 PDT, Pelthos Therapeutics Inc. (PTHS) trades at $24.55 on NYSE American. Its 52-week range is $18.18 to $37.42.
What is the market capitalisation of PTHS?
Pelthos Therapeutics Inc. (PTHS) has a market capitalisation of $93.99M on NYSE American.
What is the P/E ratio of PTHS?
PTHS trades at a trailing price-to-earnings (P/E) ratio of -0.86. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -56.06.
Is PTHS a good stock to buy?
This page provides a data-driven analysis of Pelthos Therapeutics Inc. (PTHS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.